Abstract: AIM: To explore the efficacy of urokinase used intravenously in the treatment of acute infarct. METHODS: Urokinase of 300 thousand units were added to 250ml 0.9 % normal saline intravenously, lasting for 5 days, and then changed to 100 thousand units for 5-10 d.RESULTS: The assessment of neurologic dysfunction as follows:there were no significant difference after 5 day treatment as compared with pretreatment (P> 0.05), and significant difference was noticed after 14 day treatment as compared with pretreatment (P<0.05). The status of life ability as follows:there were much significant difference after 5 day and 14 day treatment as compared with pretreatment (P<0.01).The clinical efficacy:the ratio of showing-effect was 42.86 % after 5 day treatment, and 71.43 % after 14 day treatment, and there were much significantly difference between those two groups.The fibrinogen and blood deoxidized viscosity: there were significantly difference after 5 day and 14 day treatment as compared with pretreatment (P<0.01).CONCLUSION: It is safe, effective, convenient for urokinase to treat acute infarct used intravenously, and the side effects can be avoided or reduced.

Key words: urokinase, thrombolysis, cerebral infarct